Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma
- Authors
- Kim, JG[Kim, J. G.]; Sohn, SK[Sohn, S. K.]; Chae, YS[Chae, Y. S.]; Yang, DH[Yang, D. H.]; Lee, JJ[Lee, J-J]; Kim, HJ[Kim, H-J]; Shin, HJ[Shin, H. J.]; Jung, JS[Jung, J. S.]; Kim, WS[Kim, W. S.]; Kim, DH[Kim, D. H.]; Suh, C[Suh, C.]; Kim, SJ[Kim, S. J.]; Eom, HS[Eom, H-S]; Bae, SH[Bae, S. H.]
- Issue Date
- Nov-2007
- Publisher
- NATURE PUBLISHING GROUP
- Keywords
- busulfan; cyclophosphamide; etoposide; chemotherapy; lymphoma
- Citation
- BONE MARROW TRANSPLANTATION, v.40, no.10, pp.919 - 924
- Indexed
- SCIE
SCOPUS
- Journal Title
- BONE MARROW TRANSPLANTATION
- Volume
- 40
- Number
- 10
- Start Page
- 919
- End Page
- 924
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/83703
- DOI
- 10.1038/sj.bmt.1705841
- ISSN
- 0268-3369
- Abstract
- The current study aimed to evaluate the efficacy and toxicity of a combination of intravenous busulfan, cyclophosphamide and etoposide (i.v. Bu/Cy/E) as a conditioning regimen prior to autologous hematopoietic stem cell transplantation in patients with non-Hodgkin's lymphoma (NHL). Sixty-four patients with relapsed/ refractory (n = 36) or high-risk (n = 28) lymphoma were enrolled. The high-dose chemotherapy consisted of i.v. Bu (0.8 mg kg(-1) i.v. q 6h from day -7 to day -5), Cy (50 mg kg(-1) i.v. on day -3 and day -2) and E (400 mg m(-2) i.v. on day -5 and day -4). The median age was 43 (range 18-65) years, and 39 patients were male. Diffuse large B-cell lymphoma (40.6%) was the most common histological subtype. All evaluable patients achieved an engraftment of neutrophils (median, day 12) and platelets (median, day 13). Hepatic veno-occlusive disease was observed in four patients (three mild, one moderate grade), and two patients (3.1%) died from treatment-related complications. At a median follow-up of 16.4 months, 15 patients (23.4%) exhibited a relapse or progression, while 13 patients (20.3%) had died of disease. The estimated 3-year overall and progression-free survival for all patients was 72.1 and 70.1%, respectively. In conclusion, the conditioning regimen of i.v. Bu/Cy/E was well tolerated and seemed to be effective in patients with aggressive NHL.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/83703)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.